02 December 2025 : Clinical Research
Comprehensive Plasma Oxylipin Profiling Reveals a Pro-Inflammatory Eicosanoid Signature and Diagnostic Biomarker Panel in Dilated Cardiomyopathy
Jia Wang
ABCDEF 1, Xue-qin Bai ABCDEF 1, Meng Li BCDEF 2,3, Xing-jie Wang BCF 4, Shuo-wen Sun BCF 4, Lei Huang ABCDEFG 3,5, Xu Zhang ACDEF 6,7*, Xin Chen ACDEF 1,8
DOI: 10.12659/MSM.950838
Med Sci Monit 2025; 31:e950838
Table 1 Demographic and clinical characteristics of study cohorts.
| Parameters | DCM (n=30) | Control (n=30) | t/Z/χ2 | P value |
|---|---|---|---|---|
| Male sex [n (%)] | 22 (73.3) | 22 (73.3) | <0.001 | 1.000 |
| Age | 57 (44, 63) | 58 (44, 60) | −0.096 | 0.923 |
| Heart rate (bpm) | 87 (80, 100) | 87 (82, 92) | −0.496 | 0.620 |
| SBP (mmHg) | 137.8±21.5 | 142.4±14.9 | −0.963 | 0.340 |
| Hb (g/L) | 135.4±16.0 | 137.8±11.5 | −0.669 | 0.506 |
| Alb (g/L) | 38.1±3.9 | 38.8±2.3 | −0.817 | 0.418 |
| sCr (μmol/L) | 83.1±24.4 | 90.1±23.2 | −1.144 | 0.257 |
| ALT (U/L) | 22.5 (14.0, 34.5) | 26.0 (20.0, 33.3) | −1.117 | 0.264 |
| AST (U/L) | 20.0 (15.0, 32.3) | 22.0 (18.0, 27.3) | −0.237 | 0.813 |
| TBiL (μmol/L) | 17.2 (15.0, 39.7) | 19.4 (16.1, 29.0) | −0.510 | 0.610 |
| BNP (ng/mL) | 1255 (617, 2460) | – | – | – |
| LVEF (%) | 28.5 (25.8, 33.5) | – | – | – |
| LVEDD (mm) | 64.8±8.9 | – | – | – |
| PAH (mmHg) | 43 (25, 51) | – | – | – |
| Continuous variables are presented as mean±standard deviation or median (interquartile range); categorical variables are shown as n (%). -values from t-tests or chi-square tests compare patients with DCM (n=30) and healthy controls (n=30). DCM – dilated cardiomyopathy; SBP – systolic blood pressure; Hb – hemoglobin; Alb – albumin; sCr – serum creatinine; ALT – alanine aminotransferase; AST – aspartate aminotransferase; TBiL – total bilirubin; LVEF – left ventricular ejection fraction; LVEDD – left ventricular end-diastolic diameter; PAH – pulmonary arterial hypertension. ‘–‘ – not available. | ||||